4//SEC Filing
Tincoff John M. III 4
Accession 0001213900-25-111711
CIK 0001427570other
Filed
Nov 16, 7:00 PM ET
Accepted
Nov 17, 9:11 PM ET
Size
6.9 KB
Accession
0001213900-25-111711
Insider Transaction Report
Form 4
Tincoff John M. III
Director
Transactions
- Award
Stock Option (right to buy)
2025-11-13+17,833→ 17,833 totalExercise: $0.66Exp: 2035-07-30→ Common Stock (17,833 underlying)
Footnotes (2)
- [F1]Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Vyome Therapeutics, Inc. ("Vyome Therapeutics"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the "Merger"). Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of Vyome Therapeutics outstanding immediately prior to the effective time of the Merger, whether vested or unvested, was automatically assumed by the Issuer and converted into options to purchase shares of the Issuer's common stock. As a result of the Merger, the Issuer was renamed "Vyome Holdings, Inc." and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc.
- [F2]Pursuant to the Merger Agreement the reporting person was granted 17,833 options to purchase shares of the Issuer's common stock. Of these, 4,458 options were fully vested as of the grant date. The remaining 13,375 options shall vest in twelve equal monthly installments beginning on November 30, 2025, subject to the Reporting Person's continued service on each vesting date. The options were granted under the Issuer's 2025 Equity Incentive Plan.
Documents
Issuer
Vyome Holdings, Inc
CIK 0001427570
Entity typeother
Related Parties
1- filerCIK 0002085876
Filing Metadata
- Form type
- 4
- Filed
- Nov 16, 7:00 PM ET
- Accepted
- Nov 17, 9:11 PM ET
- Size
- 6.9 KB